Experts Reviewed High-Risk Multiple Myeloma Therapies
New clinical trial insights clarify treatment options for patients with high-risk relapsed or refractory multiple myeloma.
Updated on Oct. 14, 2026 in Cancer
Dr. Hans Lee and Dr. Douglas Sborov recently discussed clinical trial data for treating high-risk, relapsed or refractory multiple myeloma. The review focused on identifying effective strategies for patients with high-risk cytogenetics and extramedullary disease.
Why it matters
High-risk multiple myeloma remains a challenging condition to treat despite significant medical advances. Analyzing clinical trial data helps clinicians better match specific treatments to a patient's unique disease characteristics.
The discussion synthesized subgroup findings from the DREAMM-7 and CARTITUDE-2 clinical trials. These studies evaluate BCMA-directed therapies and CAR T-cell treatments in populations with functionally high-risk disease features.
The players
Dr. Hans Lee
A researcher specializing in the clinical management of relapsed or refractory multiple myeloma.
Dr. Douglas Sborov
An expert in blood cancer therapies who focuses on improving outcomes for high-risk patient populations.
The details
Treatment selection for high-risk myeloma increasingly relies on identifying specific biological markers. BCMA-directed therapies and bispecific antibodies are emerging as critical tools for managing aggressive disease features like extramedullary spread. Clinicians use these data-driven insights to weigh treatment efficacy against individual patient health factors and personal preferences.
Timeline
The analysis of treatment data for high-risk multiple myeloma was published on 2026-10-14.
Health Landscape
This review builds on findings from the CARTITUDE-2 trial to refine the current standard of care for complex myeloma cases. It reflects an ongoing effort to tailor advanced immunotherapies to patients with the most aggressive disease features.
If you or a loved one are navigating high-risk multiple myeloma, discuss these latest clinical trial insights with your hematologist or oncologist. Understanding how your specific disease markers influence treatment success is a vital step in making informed care decisions.
The takeaway
Treatment for high-risk multiple myeloma is becoming increasingly personalized based on specific cytogenetic profiles. Continue to track updates on BCMA-directed therapies and discuss your disease characteristics with your care team to ensure your treatment plan reflects the latest clinical evidence.
Further reading
For more on evolving standards of care, visit our Cancer section.
Source note: This article includes information reported by OncLive.
